Thursday, October 14, 2021

Cumulus Neuroscience raises £6m in Dementia Discovery Fund-led financing round

Belfast-headquartered Cumulus Neuroscience has raised £6m in a financing round led by the Dementia Discovery Fund, with the funds set to be used to advance its integrated physiological and digital biomarker platform.

The latest financing round included new investments from the medical research charity LifeArc as well as the UK Future Fund.

Cumulus’ platform is being co-developed with ‘leading pharmaceutical companies’ with the aim of providing clinical trial data as well as artificial intelligence (AI) powered insights to speed up the development of new central nervous system (CNS) therapies.

The platform is designed to improve neuroscience trials by enabling more objective and precise assessment of drug candidates within a shorter timeline.

It captures large amounts of real-world lab-quality data, including frequent, longitudinal measurements of brain activity synchronously with a comprehensive range of functional and symptomatic domains.

Cumulus has also developed an at-home EEG headset that can objectively probe neuronal integrity, network connectivity as well as the strategies that the brain uses to compensate for neuronal damage.

The platform also provides AI-based data analysis to enable the detection of relevant changes in patients in order to produce ‘fast and meaningful’ insights, Cumulus said in a statement.

“We are delighted that DDF and LifeArc share our mission, addressing the clear need for more effective tools to provide the critical clinical trial data and analysis needed to improve the successful delivery of new CNS therapies to patients,” said Ronan Cunningham, chief executive officer of Cumulus.

“This funding will allow us to build on the ground-breaking advances we have made in remote, frequent monitoring of brain activity and cognitive function in the home, in partnership with leading developers of digital biomarkers. We believe our integrated next generation platform can improve the execution of clinical trials by yielding significant time and cost savings, adding meaningful value to the next generation of CNS therapies,” he added.

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...